L-368,899hydrochloride
- CAS No.
- 148927-60-0
- Chemical Name:
- L-368,899hydrochloride
- Synonyms
- L-368899 free base;L-368,899 hydrochlor;(2S)-2-amino-N-[(1R,3S,4S)-7,7-dimethyl-4-[[4-(2-methylphenyl)piperazin-1-yl]sulfonylmethyl]-3-bicyclo[2.2.1]heptanyl]-4-methylsulfonylbutanamide;(2S)-2-Amino-N-[(1S,2S,4R)-7,7-dimethyl-1-[[[4-(2-methylphenyl)-1-piperazinyl]sulfonyl]methyl]bicyclo[2.2.1]hept-2-yl]-4-(methylsulfonyl)butanamide;Butanamide, 2-amino-N-[(1S,2S,4R)-7,7-dimethyl-1-[[[4-(2-methylphenyl)-1-piperazinyl]sulfonyl]methyl]bicyclo[2.2.1]hept-2-yl]-4-(methylsulfonyl)-, (2S)-
- CBNumber:
- CB71075242
- Molecular Formula:
- C26H42N4O5S2
- Molecular Weight:
- 554.77
- MDL Number:
- MOL File:
- 148927-60-0.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| storage temp. | Store at +4°C |
|---|---|
| solubility | Chloroform (Slightly), Methanol (Slightly), Water (Slightly) |
| form | Solid |
| color | Off-White to Pale Yellow |
| Stability | Hygroscopic |
| FDA UNII | ER33G946JT |
L-368,899hydrochloride price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Biosynth | FD43267 | L 368899 | 148927-60-0 | 1mg | $356.95 | 2026-06-04 | Buy |
| Biosynth | FD43267 | L 368899 | 148927-60-0 | 2mg | $642.52 | 2026-06-04 | Buy |
| Biosynth | FD43267 | L 368899 | 148927-60-0 | 5mg | $1142.25 | 2026-06-04 | Buy |
| Biosynth | FD43267 | L 368899 | 148927-60-0 | 10mg | $1784.8 | 2026-06-04 | Buy |
| Biosynth | FD43267 | L 368899 | 148927-60-0 | 25mg | $3569.5 | 2026-06-04 | Buy |
L-368,899hydrochloride Chemical Properties, Uses, Production
Uses
L-368,899 Dihydrochloride is an oxytoxin antagonist and may be used in the treatment of early pregnancy failure.
Biological Activity
Potent, non-peptide and orally active oxytocin receptor antagonist (IC 50 = 8.9 nM) that displays > 40-fold selectivity over vasopressin V 1a and V 2 receptors (IC 50 values are 370 and 570 nM respectively). Antagonizes oxytocin-induced uterine contractions in vitro and in vivo .
in vivo
L-368,899 (0.1, 0.3, 1 mg/kg; infused i.v.; single) shows a dose-related antagonism of OT-stimulated uterine contractions with an AD50 value of 0.35 mg/kg in vivo[1].
L-368,899 (3, 10, 30 mg/kg; i.d.; single) inhibits the contractile effects of OT (AD50= 7 mg/kg) with a long (>4 h) duration of action in vivo (AD50: the dose of L-368,899 required to reduce the response to OT by 50%)[1].
L-368,899 (10 mg/kg, p.o.; single) shows bioavailability (AUC 0-6 h) of 35%[1].
L-368,899 (0.54, 1.8, 5.4 mg/kg; i.v.; single) reduces both oxytocin-induced and endogenous increases in plasma PGFM concentration[2].
| Animal Model: | Adult female Sprague-Dawley rats (250-350 g)[1]. |
| Dosage: | 0.1, 0.3, 1 mg/kg |
| Administration: | Infused intravenous injection; single. |
| Result: | Inhibited OT-stimulated uterine contractions with an AD50 value of 0.35 mg/kg. |
| Animal Model: | Adult female Sprague-Dawley rats (250-350 g)[1]. |
| Dosage: | 3, 10, 30 mg/kg |
| Administration: | Intraduodenal; single. |
| Result: | Exhibited a antagonism of OT-stimulated uterine contractions with an AD50 of 7 mg/kg and duration of action more than 4 h. |
| Animal Model: | Adult female Sprague-Dawley rats (250-350 g)[1]. |
| Dosage: | 10 mg/kg |
| Administration: | Oral administration, single. |
| Result: | Showed orally active with bioavailability (AUC 0-6 h) of 35%. |
| Animal Model: | Mature Dorset cross ewes (53-57 kg; Removal of ovaries)[2]. |
| Dosage: | 0.54, 1.8, 5.4 mg/kg (3, 10 and 30 μg/kg/min for 3 h; dissolved in 0.9% saline). |
| Administration: | Intravenous infusion; single. |
| Result: | Led to a significant decrease in both the frequency (from 2.2 to 1.0 episodes/ewe) and amplitude (from 68.8 to 31.8 pg/mL) of episodes of increased plasma concentration of PGFM. |
L-368,899hydrochloride Preparation Products And Raw materials
Raw materials
Preparation Products
L-368,899hydrochloride Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| 3B Pharmachem (Wuhan) International Co.,Ltd. | 18930552037 | 3bsc@sina.com | China | 15813 | 69 |
| BOC Sciences | 1-631-485-4226; 16314854226 | info@bocsci.com | United States | 9920 | 65 |
| EMMX Biotechnology LLC | 888-539-0666 | info@emmx.com | United States | 8435 | 60 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
| Shanghai Universal Biotech Co.,Ltd | 15921930842 15921930842 | yh-wang@univ-bio.com | China | 25030 | 58 |
| Nantong QuanYi Biotechnology Co., Ltd | 0513-66337626 18051384581 | sales@chemhifuture.com | China | 5985 | 58 |
| TargetMol Chemicals Inc. | 15002134094 | marketing@targetmol.cn | China | 29874 | 58 |
| Suzhou Shentuo Pharmaceutical Technology Co., Ltd | 13911244683 18151949202 | info@visonpharma.com | China | 491 | 58 |
| Henan Inokai New Materials Co., Ltd | 15090072163 | 3921118937@qq.com | China | 2676 | 58 |
| Shanghai meikai technology co., ltd | 021-68689288 15300790979 | info@mkbio.com.cn | China | 9988 | 58 |
